Figure 5

In vivo depletion experiment. C57BL/6 mice were divided into 4 groups (5/group). All mice were implanted with TC-1 (5 × 10⁴/mouse) at d0, and were then treated with imiquimod (at d2, d4, d6, d8, d10, and d12) and pcDNA-CRT/E7 2 μg (d5 and d12). Mice were either depleted of macrophages (using clodronate liposomes), NK1.1+ cells (using anti-mouse NK 1.1 mAbs, PK136), or neutrophils (using anti-mouse Gr-1 mAbs, RB6-8C5), one day before and 3 days after TC-1 implantation and thereafter once per week until the end of follow-up. Undepleted mice were used as controls. Line graph depicting the tumor sizes in tumor-bearing mice treated with the different regimens. Representative data from one of three independent experiments are shown.